upper
respiratori
system
one
common
site
infect
adult
even
children
sever
virus
variabl
famili
caus
upper
respiratori
infect
although
gener
underestim
due
typic
selflimit
natur
underli
enorm
healthcar
resourc
util
financi
burden
otherwis
benign
infect
signific
sequela
form
bring
local
complic
also
induc
asthma
attack
thu
greatli
increas
morbid
enorm
preval
also
indic
rigor
research
undertaken
order
tackl
prevent
treatment
field
upper
respiratori
tract
site
infect
sever
viral
bacteri
pathogen
term
upper
respiratori
tract
infect
urti
encompass
number
condit
variabl
divers
rang
present
due
number
adjac
anatom
site
involv
caus
organ
sever
host
environment
factor
urti
therefor
nonspecif
term
use
describ
acut
infect
involv
upper
respiratori
tract
nose
paranas
sinus
ear
pharynx
larynx
fig
howev
rather
imprecis
incorrectli
impli
absenc
lower
respiratori
tract
patholog
clearli
patholog
may
often
coexist
upper
respiratori
tract
diseas
acut
urti
import
part
gener
practic
visit
nation
studi
suggest
compris
roughli
gp
consult
viral
urti
caus
consider
financi
burden
also
associ
comorbid
often
regard
trivial
urti
receiv
attent
merit
enorm
incid
morbid
occasion
seriou
sequela
taken
consider
urti
viral
origin
human
rhinovirus
rv
parainfluenza
virus
piv
coronavirus
adenovirus
respiratori
syncyti
viru
rsv
enterovirus
human
metapneumoviru
influenza
main
culprit
tabl
human
metapneumoviru
hmpv
recent
identifi
sampl
rsvneg
children
bronchiol
human
bocaviru
bov
discov
largescal
molecular
viru
screen
pool
respiratori
tract
sampl
import
viral
agent
earli
life
clear
rsv
rv
piv
influenza
viru
predomin
literatur
howev
sever
factor
limit
understand
regard
rel
import
pathogen
includ
differ
studi
design
eg
pcr
versu
immunoassay
detect
method
recruit
criteria
investig
virus
eg
rsv
consider
easier
detect
invitro
compar
rv
transmiss
virus
caus
urti
occur
dispers
smallparticl
aerosol
droplet
largeparticl
aerosol
briefli
suspend
air
direct
contact
infecti
secret
skinenvironment
surfac
eg
direct
handtohand
contact
subsequ
passag
nare
eye
henc
transmiss
occur
easier
crowd
space
howev
transmiss
dynam
ident
differ
virus
respiratori
virus
genet
antigen
distinct
orthomyxovirida
envelop
segment
virus
includ
influenza
paramyxovirida
envelop
nonseg
virus
includ
parainfluenza
picornavirida
nonenvelop
virus
singlestrand
genom
includ
rhinovirus
enterovirus
eg
coxsacki
viru
virus
famili
coronavirida
singlestrand
rna
envelop
virus
includ
human
coronavirus
dna
virus
includ
famili
adenovirida
nonenvelop
doublestrand
dna
virus
ie
adenovirus
recentlydiscov
famili
singlestrand
dna
virus
parvovirida
eg
bocaviru
chapter
focu
agent
far
common
caus
urti
children
human
rhinoviru
tabl
agent
influenza
rsv
describ
detail
chapter
studi
use
molecular
method
shown
rv
behind
common
cold
known
host
rv
human
although
primat
may
also
host
viru
nonsymptomat
infect
histor
enterovirus
ev
rv
classifi
separ
genera
due
relat
genom
structur
merg
singl
genu
enterovirus
includ
three
rv
speci
rva
rvc
four
nonrv
ev
speci
eva
evd
fig
virus
differ
phenotyp
characterist
rv
mainli
restrict
respiratori
system
wherea
ev
caus
divers
multisystem
clinic
manifest
eg
myopericard
enceph
quit
often
viral
mening
howev
ev
caus
rvlike
respiratori
symptom
respiratori
ev
eg
speci
c
rv
ev
small
nonenvelop
rna
virus
genom
kb
pack
nm
icosahedr
capsid
turn
compos
pentam
compos
protom
protom
contain
four
capsid
protein
major
group
rv
includ
rva
rvb
typic
need
intercellular
adhes
molecul
icam
receptor
wherea
minor
group
need
low
densiti
lipoprotein
receptor
ldlr
rvc
use
differ
receptor
cadherinrel
famili
member
regard
recognit
innat
immun
system
ssrna
intern
genom
recogn
endosom
tolllik
receptor
tlr
doublestrand
rna
gener
type
interferon
ifn
respons
ensu
lead
proinflammatori
cytokin
gene
express
includ
rant
induc
protein
ip
interleukin
il
latter
potent
neutrophil
chemotacticactiv
agent
import
determin
clinic
outcom
rv
infect
product
shown
rv
infect
upper
lower
airway
epitheli
cell
antibodi
respons
rv
infect
occur
viral
clearanc
develop
neutral
serum
antibodi
igg
secretori
antibodi
iga
respiratori
tract
detect
week
infect
maintain
least
year
protect
although
humor
respons
appear
offer
crossserotyp
protect
shown
gener
protect
suboptim
oppos
influenza
viru
respiratori
syncyti
viru
rv
rare
associ
signific
cytopatholog
upper
respiratori
tract
structur
epitheli
cell
ec
line
usual
remain
intact
viral
shed
rel
limit
consid
sever
symptom
howev
rv
disrupt
function
epithelium
facilit
exposur
epitheli
cell
bacteria
allergen
irrit
children
consid
major
reservoir
rv
could
experi
common
cold
infect
per
year
averag
incub
period
day
symptom
durat
day
two
main
peak
infect
first
around
aprilmay
second
around
septemberoctob
northern
hemispher
although
infect
gener
seen
year
round
rv
urti
typic
induc
nasal
congest
rhinorrhea
cough
sneez
sore
throat
malais
lowgrad
fever
airway
epithelium
primari
site
infect
rv
viral
transmiss
occur
mainli
via
direct
contact
fomit
typic
inocul
nasal
mucosa
eye
conjunctiva
transport
via
lachrym
duct
nasal
caviti
transmiss
larg
particl
aerosol
less
common
probabl
less
effici
rv
surviv
surfac
skin
sever
hour
allow
easi
transmiss
absenc
adequ
hygien
one
classic
studi
viral
inoculum
right
conjunctiv
sac
led
posit
cultur
rv
initi
nasopharynx
afterward
inferior
turbin
presum
spread
via
nose
blow
two
decad
ago
believ
rv
could
infect
lower
airway
grow
best
henc
viru
replic
thought
reduc
core
temperatur
found
lung
howev
shown
rv
replic
lower
airway
epitheli
cell
differ
replic
capac
higher
temperatur
minim
shown
eight
differ
rv
strain
whose
titer
significantli
higher
requir
initi
infect
provid
conclus
evid
infectionrel
mechan
underli
epidemiolog
link
common
cold
asthma
exacerb
twothird
virusinduc
asthma
attack
due
rv
probabl
result
local
system
immun
respons
local
cytopatholog
bronchial
epitheli
cell
observ
use
high
viral
inocula
suggest
potenti
doserespons
relationship
patient
asthma
may
particularli
suscept
well
recogn
rv
strictli
upper
respiratori
pathogen
fact
one
power
earli
factor
associ
asthma
throughout
childhood
dynam
rv
infect
affect
atop
individu
although
still
clear
extent
increas
suscept
viru
andor
differenti
respons
context
shown
atop
children
asthma
higher
rate
symptomat
cold
asthmat
episod
nonatop
children
long
time
clinician
suspect
upper
respiratori
infect
major
caus
asthma
exacerb
season
strong
peak
asthma
morbid
septemb
temper
climat
shortli
children
return
school
correspond
close
pattern
rv
identif
use
novel
time
pcrbase
viral
diagnost
viral
presenc
detect
exacerb
pediatr
asthma
approxim
twothird
associ
rv
although
normal
steadyst
viral
presencerath
infect
exclud
case
shown
children
present
asthma
exacerb
posit
viral
genet
materi
versu
healthi
control
rv
detect
case
coronavirus
influenza
parainfluenza
virus
rsv
well
establish
rv
potent
trigger
asthma
exacerb
reduc
interferon
respons
asthmat
children
thought
potenti
mechan
underli
rvinduc
asthma
attack
numer
longitudin
studi
demonstr
rv
infect
preced
develop
asthma
birth
cohort
highrisk
infant
childhood
origin
asthma
coast
shown
wheezingassoci
ill
rv
probabl
import
risk
factor
futur
asthma
birth
cohort
studi
also
demonstr
doserespons
relationship
infant
rti
sever
asthma
risk
among
infant
lrti
preval
rv
approxim
rv
infect
confer
much
higher
risk
futur
asthma
develop
allergen
sensit
rsv
infect
alon
insofar
certain
strain
rv
directli
infect
activ
cell
earlylif
alter
immun
respons
rv
could
strain
specif
rather
ill
sever
specif
taken
togeth
data
suggest
either
earli
rv
infect
caus
futur
asthma
may
simpli
reveal
preexist
tendenc
asthma
latter
true
earli
wheezingassoci
ill
due
rhinoviru
essenti
viralinduc
asthma
exacerb
support
hypothesi
recent
shown
children
asthma
age
seven
lung
function
deficit
increas
bronchial
respons
earli
neonat
age
howev
current
consensu
detail
unclear
regard
direct
relationship
earli
rhinoviru
infect
futur
asthma
shown
rv
consider
cytotox
even
though
replic
caus
cell
lysi
princip
method
releas
progeni
viru
rv
infect
small
subset
cell
lysi
extens
damag
epithelium
could
instead
exist
mechan
wherebi
earlylif
rv
infect
might
perman
alter
lung
immun
develop
airway
physiolog
rv
infect
appear
induc
immun
respons
interferon
releas
caus
malais
myalgia
neural
activ
promot
sneezingsor
throatcough
well
mediat
releas
infect
cell
leucocyt
rvinfect
epitheli
cell
releas
varieti
chemokin
promot
recruit
neutrophil
mononuclear
cell
neonat
mous
model
rv
infect
result
prolong
asthmalik
respons
depend
furthermor
extracellular
matrix
collagen
deposit
increas
rvinfect
cultur
human
bronchial
ec
shown
local
induct
proinflammatori
mediat
rv
infect
name
increas
mrna
express
subsequ
releas
rant
cc
chemokin
chemoattract
activ
eosinophil
monocyt
lymphocyt
produc
enhanc
airway
smooth
muscl
contract
attenu
smooth
muscl
dilat
respons
bronchodil
preexist
asthma
may
hinder
antivir
respons
studi
experiment
rv
inocul
demonstr
asthma
associ
increas
neutrophil
product
asthma
phenotyp
associ
increas
express
princip
receptor
rv
might
also
associ
increas
suscept
complic
rv
infect
chronic
allergen
exposur
also
increas
epitheli
express
also
true
rv
infect
product
current
approv
antivir
agent
prevent
treatment
rv
infect
vaccin
develop
tradit
hinder
exist
rv
serotyp
treatment
remain
primarili
support
focus
symptom
relief
date
rv
vaccin
use
clinic
alongsid
consider
serotyp
variabl
vaccin
develop
hinder
incomplet
understand
antigen
differ
recent
discov
rvc
speci
rva
b
speci
also
recent
anim
model
experiment
rv
infect
develop
due
rv
dedic
human
pathogen
wild
form
recent
research
work
focus
deriv
antigen
peptid
recogn
crossneutr
antibodi
viral
capsid
protein
clinicallyapplic
vaccin
still
far
road
regard
medic
prevent
treatment
oppos
vaccin
investig
approach
date
includ
interferon
ifn
inhibitor
viral
attach
entri
inhibitor
viral
proteas
intranas
recombin
use
sever
decad
ago
modest
efficaci
shown
prophylact
use
safetywis
longterm
administr
associ
nasal
irrit
mucos
histolog
chang
treatment
alreadi
establish
infect
intranas
ifn
ineffect
regard
attach
entri
inhibitor
intranas
tremacamra
boehring
ingelheim
ridgefield
ct
solubl
form
design
interfer
attach
rv
target
host
cell
demonstr
small
effect
symptom
score
howev
given
hour
viral
challeng
efficaci
unclear
regard
capsid
bind
agent
pleconaril
develop
submit
approv
us
fda
succeed
reduc
symptom
durat
day
howev
side
effect
presum
drug
resist
led
fda
declin
approv
none
sever
agent
investig
research
trial
found
way
clinic
new
molecular
diagnost
tool
allow
discoveri
new
speci
rv
rvc
sinc
discoveri
rvc
report
high
preval
resembl
rva
rather
rvb
season
seem
differ
rv
speci
peak
winter
month
temper
subtrop
countri
reach
peak
earli
fall
late
spring
tropic
countri
raini
season
limit
research
conduct
rvc
far
due
lack
human
experiment
model
viru
inabl
grow
standard
cell
line
howev
report
far
portray
predomin
speci
high
virul
associ
acut
occasion
sever
respiratori
ill
young
children
experi
wheez
ill
due
rvc
like
develop
recurr
wheez
compar
virus
three
type
rvc
shown
grow
equal
well
could
facilit
develop
lower
respiratori
tract
infect
lrti
wheez
ill
rvc
infect
respiratori
viru
infect
often
confin
upper
respiratori
tract
rhiniti
pharyng
frequent
associ
conjunctiv
ear
patholog
infant
urti
often
accompani
fever
may
lead
lethargi
poor
feed
variou
techniqu
includ
nasal
swab
aspir
brush
wash
use
collect
nasal
specimen
effect
respiratori
virus
gener
diagnos
either
follow
way
viru
cultur
serolog
immunofluorescenceantigen
detect
nucleic
acidpcrbas
test
viru
cultur
cell
line
infect
virus
wherea
serolog
blood
test
virusspecif
antigenantibodi
method
oner
slow
produc
result
therefor
use
routin
clinic
work
role
epidemiolog
context
antigen
detect
antigen
specif
monoclon
antibodi
basi
varieti
rapid
diagnost
test
howev
demonstr
rel
low
sensit
adult
viral
load
may
low
nucleic
acidbas
test
increasingli
use
open
new
avenu
research
especi
rv
method
suboptim
also
multiplex
allow
rapid
concurr
detect
mani
virus
includ
rv
influenza
viru
adenoviru
rsv
human
metapneumoviru
piv
sever
rapid
antigen
test
also
develop
certain
virus
ifv
rsv
recommend
regard
use
test
especi
influenza
produc
specif
guidelin
base
variou
criteria
eg
institut
outbreak
travel
surveil
system
indic
influenza
circul
commun
recommend
use
rapid
test
influenza
diagnosi
urti
indic
use
rapid
antigen
test
clinic
diagnost
test
viral
urti
gener
recommend
routin
clinic
practic
unless
special
circumst
eg
complic
differenti
diagnosi
issu
immunocompromis
individu
etc
current
develop
new
chip
detect
antibodi
respons
differ
rv
subtyp
context
predicta
eu
project
tool
may
abl
use
urti
futur
although
role
radiolog
studi
viral
urti
limit
potenti
intracrani
sequala
evalu
comput
tomographi
ct
magnet
reson
imag
mri
current
drug
respiratori
virus
use
everyday
practic
influenza
lower
respiratori
infect
sever
drug
antivir
activ
mainli
act
nucleosid
analogu
inhibit
dnarna
polymeras
use
gener
use
urti
brief
mention
made
import
detail
mainli
develop
lower
respiratori
tract
infect
beyond
scope
chapter
ribavirin
develop
influenza
drug
promis
result
anim
model
sever
decad
ago
unclear
result
human
forc
fda
declin
approv
influenza
use
offlabel
treat
rv
rsv
infect
immunocompromis
host
hospit
infant
sever
lower
respiratori
infect
poor
safeti
profil
gener
longer
use
influenza
infect
lower
airway
oseltamivir
tamiflu
zanamivir
relenza
two
neuraminidas
inhibitor
histor
use
current
former
main
medic
use
influenza
activ
influenza
b
nt
typic
induc
viral
resist
agent
replac
adamantan
amantadin
rimantadin
channel
blocker
activ
influenza
also
caus
widespread
resist
current
recommend
clinic
use
current
licens
vaccin
parainfluenza
variou
agent
evalu
clinic
trial
eg
regard
adenoviru
oral
vaccin
use
decad
usa
militari
train
instal
regard
treatment
andor
prevent
rsv
infect
sever
compound
current
clinic
develop
novel
oral
benzodiazepin
fusion
inhibitor
fprotein
inhibitor
sirna
other
furthermor
palivizumab
reduc
rsv
hospit
highrisk
infant
motavizumab
shown
effect
agent
describ
detail
chapter
book
specif
condit
common
cold
mild
selflimit
ill
viral
origin
gener
character
upper
respiratori
tract
symptom
essenti
syndrom
caus
sever
differ
virus
common
culprit
rv
also
caus
coronaviru
rsv
influenza
viru
piv
adenoviru
metapneumoviru
bov
occasion
ev
implic
summer
common
cold
occur
yearround
less
warmer
month
cold
temperatur
may
facilit
symptomat
present
shown
import
anim
studi
temperatur
chang
directli
impact
virushost
interact
weaken
innat
immun
respons
infect
common
cold
clinic
syndrom
rhiniti
upper
respiratori
sign
symptom
includ
rhinorrhea
sore
throat
sneez
cough
wateri
eye
symptomatolog
pathognomon
specif
viral
agent
although
differ
sever
specif
symptom
distinct
virus
eg
conjunct
characterist
seen
adenoviru
infect
commonli
nasal
congest
sneez
rhinorrhea
form
initi
present
cough
sore
throat
occasion
lowgrad
fever
follow
symptom
usual
peak
day
onset
decreas
around
day
usual
resolv
spontan
day
incub
period
could
vari
significantli
depend
viru
day
influenza
hour
influenza
b
day
coronaviru
day
rsv
day
adenoviru
hour
rv
laboratori
test
requir
diagnosi
common
cold
clinic
pictur
diagnost
although
largescal
pcrbase
molecular
screen
viral
genom
sequenc
continu
identifi
new
causal
agent
test
need
gener
practic
alter
manag
knowledg
infect
agent
offer
significantli
treatment
apart
potenti
reduc
excess
use
antibiot
allow
appropri
cohort
hospit
patient
reduc
nosocomi
infect
rapid
test
bacteria
may
howev
indic
concern
differenti
diagnosi
microbi
infect
gener
treatment
symptomat
common
cold
syndrom
develop
antivir
specif
viral
agent
offer
littl
relief
major
patient
furthermor
antibiot
role
treatment
consist
ill
viral
etiolog
increas
oral
fluid
intak
appear
benefit
suffici
evid
use
complementari
altern
therapi
antiinflammatori
drug
may
reliev
discomfort
significantli
control
symptom
alter
cours
diseas
oppos
second
gener
antihistamin
ineffect
firstgener
antihistamin
improv
rhinorrhea
due
antiholinerg
properti
given
children
combin
decongest
effect
compromis
safeti
profil
formul
topic
ipratropium
reduc
rhinorrhea
sneez
effect
nasal
congest
probiot
margin
effect
prevent
durat
cold
common
complic
includ
acut
otiti
media
sinus
due
culprit
viru
bacteri
superinfect
occur
rang
patient
superimpos
bacteri
rhinosinus
may
experi
symptom
sever
week
common
cold
includ
facial
pain
headach
purul
nasal
discharg
young
children
viral
pneumonia
could
sever
complic
parainfluenza
rsv
bacteri
pneumonia
could
sequela
influenza
infect
rv
isol
children
hospit
communityacquir
pneumonia
also
laryngotracheobronch
bronchiol
usual
start
urti
postvir
olfactori
disord
includ
parosmia
hyposmia
anosmia
frequent
seen
children
seen
around
adult
case
presum
due
increas
impair
olfact
seen
age
immunocompromis
children
primari
immunodefici
organ
transplant
malign
hivinfect
diabet
autoimmun
diseas
suscept
increas
morbid
includ
icu
admiss
increas
mortal
viral
urti
sinus
one
three
common
health
care
complaint
although
typic
selflimit
diseas
rank
among
top
costli
condit
us
defin
inflamm
mucou
membran
paranas
sinus
fig
may
trigger
viral
bacteri
fungal
infect
often
start
alway
involv
nasal
caviti
henc
term
rhinosinus
wide
accept
use
acut
rhinosinus
ar
divid
acut
viral
rhinosinus
acut
bacteri
rhinosinus
although
case
communityacquir
acut
rhinosinus
due
bacteria
vast
major
viral
origin
ar
usual
preced
viral
rhiniti
common
cold
fact
common
cold
would
often
induc
rhiniti
sinus
detect
ct
mri
report
common
symptom
includ
nasal
congest
reduc
sens
smell
facial
pressurepain
rhinorrhea
fevermalais
symptom
peak
within
day
onset
declin
gradual
thereaft
resolv
within
day
symptom
common
cold
worsen
day
persist
longer
day
prolong
andor
sever
normal
expect
diagnosi
ar
either
viral
bacteri
probabl
diagnosi
ar
base
symptom
durat
also
endoscop
radiolog
test
seen
tabl
standard
sinu
radiograph
may
use
diagnosi
acut
frontal
maxillari
sinus
necessari
ar
diagnos
next
step
would
distinguish
acut
bacteri
rhinosinus
case
viral
rhinosinus
base
patient
medic
histori
physic
examin
gener
ill
cours
appear
longer
bacteri
rs
guidelin
regard
cours
diseas
vari
sahp
guidelin
support
diagnosi
acut
bacteri
rhinosinus
patient
whose
uri
resolv
day
worsen
day
aaaaiacaai
guidelin
appli
longer
timefram
persist
uri
symptom
day
suspect
acut
bacteri
rhinosinus
clinic
research
sinu
punctur
use
confirm
acut
bacteri
rhinosinus
procedur
warrant
gener
practic
except
patient
infect
resist
treatment
immunocompromis
host
andor
intracranialorbit
complic
chronic
sinus
clinic
manifest
gener
acut
diseas
last
week
detail
discuss
chronic
rhinosinus
beyond
scope
chapter
viral
rhinosinus
need
support
treatment
focus
symptom
relief
condit
selflimit
patient
symptom
persist
day
without
improv
sever
symptom
fever
purul
nasal
discharg
facial
pain
doubl
sicken
ill
character
initi
improv
typic
viral
uri
follow
deterior
possibl
acut
bacterialrath
viralrhinosinus
empir
antimicrobi
therapi
initi
treatment
acut
bacteri
sinus
aim
erad
bacteri
growth
sinus
restor
ventil
drainag
decreas
inflammatori
process
firstchoic
antibiot
includ
amoxicillin
secondor
thirdgener
cephalosporin
amoxicillin
plu
clavulan
acid
use
topic
corticosteroid
may
consid
better
control
symptom
specif
case
viral
rhinosinus
induc
local
chang
increas
risk
bacteri
superinfect
eg
epitheli
damag
mechanicalhumoralcellular
alter
etc
howev
bacteri
superinfect
seen
case
viral
inflamm
nose
paranas
sinus
character
two
symptom
one
must
nasal
blockageobstructioncongest
ii
nasal
discharg
anteriorposterior
nasal
drip
iii
facial
painpressur
iv
reduct
loss
smell
one
follow
endoscop
sign
either
polyp
ii
mucopurul
discharg
mainli
middl
meatu
iii
edemamucos
obstruct
primarili
middl
meatu
comput
tomographi
chang
mucos
chang
within
ostiomeat
complex
ii
sinus
guidelin
applic
adult
children
chronic
rs
symptom
last
week
intermitt
continu
rhinosinus
bacteria
usual
involv
descend
order
frequenc
haemophilu
influenza
streptococcu
pneumonia
staphylococcu
aureu
moraxella
catarrhali
complic
may
rare
occur
nearbi
structur
orbit
eg
orbit
cellul
brain
eg
cerebr
abscess
persist
repeat
acut
sinus
may
lead
chronic
sinus
symptom
week
cr
often
link
chronic
lung
diseas
especi
sever
asthma
acut
pharyng
defin
infect
pharynx
andor
tonsil
describ
syndrom
sore
throat
fever
pharyng
inflamm
common
among
children
adolesc
virus
caus
acut
pharyng
episod
rv
coronaviru
adenoviru
account
roughli
pharyng
case
epsteinbarr
influenza
piv
tabl
mani
microb
also
caus
pharyng
group
streptococcu
also
known
streptococcu
pyogen
caus
total
case
children
older
year
culprit
bacteria
group
c
streptococcu
total
case
clamydophila
pneumonia
mycoplasma
pneumonia
tabl
diseas
character
pharyng
sore
irrit
common
symptom
shown
tabl
pharyngoconjunctiv
fever
seen
adenoviru
case
may
present
conjunct
characterist
find
viru
acut
lymphonodular
pharyng
may
caus
coxsacki
viru
distinguish
characterist
nonvesicular
erupt
uvula
soft
palat
anterior
tonsillar
pillar
posterior
pharynx
lesion
consist
multipl
rais
discret
papul
surround
erythemat
halo
herpangina
also
caus
coxsacki
virus
character
diffus
erythema
vesicular
erupt
posterior
oral
mucosa
oropharynx
ruptur
leav
pain
ulcer
young
children
typic
infecti
mononucleosi
syndrom
caus
epsteinbarr
viru
clinic
character
sore
throat
fever
lymphadenopathi
occasion
characterist
palat
petechia
import
identifi
case
acut
pharyng
caus
strep
pyogen
main
agent
requir
specif
antibiot
therapi
clinic
sign
help
tell
apart
viral
bacteri
case
show
consider
overlap
singl
element
patient
histori
physic
examin
reliabl
detect
etiolog
subtl
sign
help
howev
includ
diseas
cours
onset
viral
pharyng
may
gradual
symptom
often
includ
rhinorrhea
cough
diarrhea
hoars
bacteri
cultur
throat
swab
use
diagnosi
streptococc
pharyng
practic
routin
use
rapid
antigen
detect
test
radt
highli
specif
provid
immedi
result
thu
often
use
routin
daili
practic
clinic
pictur
suggest
infecti
mononucleosi
im
diagnosi
may
aid
posit
heterophil
antibodi
test
paulbunnel
spot
test
high
sensit
second
week
ill
investig
rare
requir
caus
viral
pharyng
diagnosi
clinic
one
manag
requir
viral
pharyng
support
measur
strep
pyogen
pharyng
penicillin
v
amoxycilin
treatment
choic
complic
distinguish
suppur
nonsuppur
suppur
complic
mainli
due
spread
culprit
agent
adjac
tissu
case
strep
pyogen
includ
peritonsillarretropharyng
abscess
cervic
lymphaden
otiti
media
mastoid
sinus
complic
except
abscess
seen
viral
pharyng
well
nonsuppur
immunemedi
sequela
mainli
associ
strep
pyogen
rather
virus
includ
acut
rheumat
fever
arf
acut
poststreptococc
glomerulonephr
acut
otiti
media
aom
patholog
middl
ear
mucosa
tympan
membran
behind
ear
drum
complic
approxim
one
third
coldlik
viral
urti
earli
childhood
case
rsv
adenoviru
cytomegaloviru
piv
adenoviru
enteroviru
influenza
viru
identifi
rv
increasingli
appreci
caus
condit
otolog
manifest
rv
infect
includ
eustachian
tube
dysfunct
abnorm
middl
ear
pressur
main
caus
thought
underli
aom
rv
detect
realtim
pcr
nasopharyng
aspir
middl
ear
fluid
specimen
episod
aom
children
nasal
inocul
viru
rsv
caus
acut
otiti
media
approxim
case
account
onethird
viral
caus
otiti
media
effus
ome
condit
often
follow
slowli
resolv
aom
effus
gluelik
fluid
behind
intact
tympan
membran
absenc
sign
acut
inflamm
rv
predomin
viru
recov
team
middl
ear
caviti
children
asymptomat
ome
aom
typic
short
histori
commonli
associ
fever
otalgia
irrit
otorrhea
lethargi
anorexia
vomit
symptom
alon
lack
sensit
specif
diagnosi
otoscopi
vital
make
diagnosi
sensit
specif
respect
may
increas
use
pneumat
otoscopi
clinic
find
variabl
includ
abnorm
color
eg
yellow
amberblu
retractedconcav
tympan
membran
airfluid
level
addit
test
audiometri
tympanometri
could
use
necessari
set
diagnosi
aom
viral
aom
need
specif
treatment
bacteri
aom
gener
follow
mild
cours
without
antibiot
treatment
support
measur
analgesia
antipyret
import
case
approxim
children
spontan
relief
aom
within
day
suggest
simpl
monitor
may
suffici
howev
alway
case
differ
societi
produc
guidelin
regard
antibiot
administ
acut
mastoid
seriou
uncompl
aom
typic
requir
hospit
admiss
intraven
antibiot
surgeri
abscess
form
mastoid
respond
initi
therapi
coinfect
bacteri
pathogen
common
viral
aom
episod
one
studi
bacterialvir
coinfect
occur
patient
picornavirus
account
twothird
case
rel
common
complic
aom
acut
mastoid
defin
acut
inflamm
mastoid
periosteum
patient
usual
present
symptom
aom
plu
postauricular
swell
mastoid
tender
sever
complic
usual
seen
often
microbi
otiti
includ
mening
epiduralbrain
abscess
thrombosi
lateralcavern
sinu
other
acut
obstruct
may
present
supraglott
glottic
subglott
region
edema
develop
area
reduc
radiu
airway
lumen
subsequ
airflow
similar
pathophysiolog
background
confin
anatom
space
wherein
condit
develop
fig
share
sever
sign
symptom
regardless
underli
caus
viral
tracheiti
viral
croup
far
commonest
condit
viral
croup
common
ill
character
inflamm
larynx
defin
acut
clinic
syndrom
inspiratori
stridor
bark
cough
hoars
variabl
degre
respiratori
distress
million
case
diagnos
annual
account
one
third
patient
present
acut
cough
viral
croup
commonest
form
croup
account
laryngotrach
infect
peak
incid
second
year
life
affect
children
age
month
year
although
typic
caus
piv
especi
type
piv
respiratori
virus
caus
croup
rv
rsv
adenoviru
hmpv
influenza
viru
cov
hbov
describ
caus
croup
variabl
incid
rv
detect
often
sampl
obtain
fall
wherea
influenza
rsv
common
winter
piv
mainli
found
winter
spring
symptom
develop
mainli
due
airway
obstruct
short
histori
preced
viral
ill
sore
throat
coryza
fever
patient
present
characterist
bark
cough
harsh
inspiratori
stridor
occasion
variabl
degre
respiratori
distress
evidenc
increas
effort
breath
intercostalsubcost
recess
grunt
nasal
flare
etc
often
howev
present
mild
viral
croup
clinic
diagnosi
test
need
conduct
diagnos
uncompl
croup
undertaken
later
neck
film
may
show
subglott
narrow
classic
steepl
sign
fig
plain
neck
radiograph
could
help
differenti
diagnos
retropharyng
abscess
epiglott
foreign
bodi
aspir
direct
laryngoscopi
rare
indic
episod
usual
selflimit
racem
epinephrin
nebul
reduc
subglott
edema
help
howev
note
benefici
effect
nebul
epinephrin
transient
current
treatment
system
dexamethason
prefer
via
oral
rout
fewer
hospit
admiss
croup
requir
intub
spasmod
croup
caus
directli
virus
bacteria
almost
alway
occur
night
children
previous
well
mild
urti
occasion
indistinguish
viral
croup
possibl
repres
condit
within
spectrum
classic
child
awaken
barki
cough
inspiratori
stridor
fever
present
exposur
moist
night
air
typic
help
resolv
symptom
etiolog
airway
edema
unclear
may
caus
allerg
reaction
viral
antigen
howev
direct
viral
involv
usual
patient
histori
allerg
diseas
treatment
ident
viral
croup
acut
epiglott
supraglott
infect
epiglotti
diseas
histor
caus
haemophilu
influenza
type
b
hib
howev
develop
hib
vaccin
alter
trend
rare
case
epiglott
immun
child
mostli
due
haemophilu
parainfluenza
aureu
streptococcu
pneumonia
condit
caus
bacteria
rather
virus
detail
descript
beyond
scope
chapter
briefli
discuss
section
alongsid
bacteri
tracheiti
purpos
differenti
diagnosi
condit
easili
escal
complet
airway
obstruct
classic
clinic
present
toxiclook
child
sever
anxieti
sore
throat
soft
inspiratori
stridor
dysphagia
high
fever
drool
usual
minim
cough
radiolog
requir
set
diagnosi
undertaken
inflam
swollen
epiglotti
give
characterist
thumb
sign
antibiot
usual
cefotaxim
ceftriaxon
must
commenc
promptli
condit
easili
told
apart
viral
coup
toxic
appear
child
high
fever
lack
cough
histori
sever
sore
throat
dysphagia
bacteri
tracheiti
pseudomembran
croup
anoth
condit
character
bacteri
inflamm
tracheal
mucosa
infect
staphyloccocu
aureu
streptococci
haemophilu
influenza
b
hib
patient
appear
toxic
high
fever
progress
upper
airway
obstruct
oppos
epiglott
characterist
barki
cough
promin
typic
drool
intraven
antibiot
typic
flucloxacillin
cefotaxim
given
urti
preval
patholog
condit
consider
caus
morbid
increas
financi
burden
health
system
societi
sever
sequala
although
rare
could
caus
mortal
signific
disabl
import
condit
grossli
underestim
need
acknowledg
signific
health
problem
especi
sinc
prescript
antibiot
steadili
lead
danger
treatmentresist
form
diseas
